James L Wade

  • 8501 Citations
1984 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Internal Medicine
Medical Oncology

Training Experience

1981Residency, Univ. of Illinois Hospital
1984Fellowship, University of Chicago Hospitals

Education/Academic qualification

MD, University of Illinois - Chicago

… → 1978

Fingerprint Dive into the research topics where James L Wade is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Placebos Medicine & Life Sciences
Medical Oncology Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Aromatase Inhibitors Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1984 2019

  • 8501 Citations
  • 71 Article
  • 11 Review article

Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202

Henry, N. L., Unger, J. M., Till, C., Schott, A. F., Crew, K. D., Lew, D. L., Fisch, M. J., Moinpour, C. M., Wade, J. L. & Hershman, D. L., Jun 15 2019, In : Cancer. 125, 12, p. 2123-2129 7 p.

Research output: Contribution to journalArticle

Aromatase Inhibitors
Body Mass Index
Pain
Placebos
Obesity

Effective stakeholder engagement: Design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care

Barger, S., Sullivan, S. D., Bell-Brown, A., Bott, B., Ciccarella, A. M., Golenski, J., Gorman, M., Johnson, J., Kreizenbeck, K., Kurttila, F., Mason, G., Myers, J., Seigel, C., Wade, J. L., Walia, G., Watabayashi, K., Lyman, G. H. & Ramsey, S. D., Jun 11 2019, In : BMC Medical Research Methodology. 19, 1, 119.

Research output: Contribution to journalArticle

Open Access
Clinical Trials
Research
Neoplasms
Pragmatic Clinical Trials
Guidelines
9 Citations (Scopus)

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study

Owonikoko, T. K., Dahlberg, S. E., Sica, G. L., Wagner, L. I., Wade, J. L., Srkalovic, G., Lash, B. W., Leach, J. W., Leal, T. B., Aggarwal, C. & Ramalingam, S. S., Jan 20 2019, In : Journal of Clinical Oncology. 37, 3, p. 222-229 8 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Disease-Free Survival
Placebos

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Langer, C. J., Redman, M. W., Wade, J. L., Aggarwal, C., Bradley, J. D., Crawford, J., Stella, P. J., Knapp, M. H., Miao, J., Minichiello, K., Herbst, R. S., Kelly, K., Gandara, D. R. & Papadimitrakopoulou, V. A., Jan 1 2019, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Squamous Cell Neoplasms
Lung Neoplasms
Medical Futility
Population
1 Citation (Scopus)

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

TRINOVA-3/ENGOT-ov2/GOG-3001 investigators, Jun 1 2019, In : The Lancet Oncology. 20, 6, p. 862-876 15 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Ovarian Neoplasms
Placebos
Disease-Free Survival